Allergan acquires Topokine Therapeutics

DUBLIN and BOSTON — Allergan on Thursday announced that it had acquired topical dermatology company Topokine Therapeutics, which develops medicine for fat reduction.

 

The acquisition saw Allergan pauying $85 million up front alongside success-based development and milestones for Topokine’s XAF5, an under-eye bag treatment. 

 

"The acquisition of Topokine and its XAF5 technology adds an innovative technology to Allergan's industry leading mid-to-late stage pipeline of more than 70 programs and bolsters our leadership in medical aesthetics," said David Nicholson, EVP and president of global brands research and development at Allergan. "XAF5 has the potential to be the first topical fat reduction product for the treatment of steatoblepharon, a condition with no current therapeutic options available for patients. We look forward to continuing the outstanding development work conducted by the Topokine team to bring this innovative medical aesthetic treatment to market."